Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > 313 millions shares outstanding...
View:
Post by wildbird1 on Mar 12, 2023 11:55am

313 millions shares outstanding...

Let's talk about TLT shares counts.

As we speak almost all the heavy works in TLT bladder cancer trial has been done, and if there is a need for financing, it will be minimal.
Future PP for other cancer trials will be done at a much higher SP, and will also be financed with the help of a large Pharma JV money deal.
The above should limit future dillution to a bare minimum.

TLT has approximately 313 millions shares outstanding(warrants & options included).
Question?
Is 313 millions shares outstanding a big number?
Answer.
It depend on the value($) of TLT market opportunity.
A) In the June 28,2022 Market Presentation, TLT said " the market opportunity for the BCR-Unresponsive is approximately +2 to 5 billions$/year".
B) The next step for TLT, will be to go after  the BCG-Shortage market, +5 to 10 billions$/year.
C) Next Lung(NSCLC) + XX billions$/year.
D) Next Brain(GBM)    + XX billions$/year.
If you take into account only the BCG-Unresponsive market opportunity value($), then 313 millions is a puny little number of shares.

Question?
Is it possible for a pharma company that has a colossal 5.6 Billion shares outstanding to be a successful pharma company?
Answer yes.
Pfizer has a colossal 5.6 Billion shares outstanding, and is a successful pharma company.

In short...
I agree... TLT is not Pfizer, but with a puny little 313 millions shares outstanding, TLT has a lot's of room to spare on the shares counts.
And if there is a need for money, bring it on, with the huge market opportunities TLT has, the financing, and the shares counts will not stop TLT from being successful.

2023 is the year of TLT (not 2025).
Comment by Oilminerdeluxe on Mar 12, 2023 12:55pm
My kingdom for an update.
Comment by N0taP00p on Mar 12, 2023 2:50pm
 Let's get to $5 first, which is kinda where SESN settled based on NMIBC focus before they imploded.  A BTD could get us to $5 range in the hopes of a JV or buyout.  Their corporate presentation still binds the top end total market at ~$2B for BCG resistant NMIBC. I missed the expansion to $5B total available market. I don't see it in their June 28th release. Can you provide ...more  
Comment by Eoganacht on Mar 12, 2023 10:42pm
It's on page 7 of the current Corporate Presentation.
Comment by N0taP00p on Mar 12, 2023 11:00pm
Thank you, Eoganacht. $5 with BTD seems like a no brainer then. At the minimum, at a conservative 1X of sales (MC) assuming 30% revenue share of the top end. 
Comment by Yajne on Mar 13, 2023 12:35pm
Is June 2022 their latest corp presentation? Must be my imagination but I thought there was something more recent... 
Comment by DeathXray33 on Mar 12, 2023 4:07pm
If I own over 1 million and increasing; so do many here and insiders, it wouldn't take much to get this going. My sense is tingling...
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250